the aid library

LIST OPTIONS

Filter

12473

Sort by:

Direction:

Download (141)

View PDF (158)

Framework for collaborative action on tuberculosis and comorbidities

World Health Organization WHO (2022) C_WHO

Addressing comorbidities and risk factors for TB is a crucial component of Pillar one of the End TB Strategy, which focuses on integrated patient-centred care and prevention, including action on TB and comorbidities. The Framework for collaborative action on TB and comorbidities aims to support coun... more

Download (211)

View PDF (270)

Clinical management and infection prevention and control for monkeypox
recommended

World Health Organization WHO (2022) C_WHO

Interim rapid response guidance, 10 June 2022. It includes considerations for certain populations such as patients with mild disease with considerations for community care, patients with moderate to severe disease, sexually active persons, pregnant or breastfeeding women, children and young persons... more

Download (575)

View PDF (1025)

Laboratory testing for Zika virus and dengue virus infections: interim guidance
recommended

World Health Organization (2022) C_WHO

Zika and dengue viruses remain significant public health threats. These viruses share the same Aedes (Stegomyia) mosquito vectors and geographic distributions but infections cannot be readily distinguished clinically and need to be differentiated from each other, and from other circulating arboviral... more

Download (166)

View PDF (234)

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV
recommended

World Health Organization WHO (2020) C_WHO

Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum. This disease is highly endemic in some regions of North America, Central America, and South America and is also reported in certain countries of Asia and Africa. It often affects people with impaired immunity, including people ... more

Download (114)

View PDF (141)

Monitoring and evaluation framework
recommended

World Health Organization WHO (2020) CC

COVID‑19 strategic preparedness and response

Download (74)

View PDF (118)

Gender and noncommunicable diseases in Ukraine: analysis of STEPS data

World Health Organization WHO, Regional Office of Europe (2020) C_WHO

This report is part of the gender and noncommunicable diseases (NCDs) initiative launched by the WHO Regional Office for Europe, which aims to strengthen the response to NCDs through a gender approach. It is part of a series of country profiles and a synthesis report. The country profile of Ukraine ... more

Download (213)

View PDF (300)

Roadmap for introduction and roll‐out of Merck rVSV‐ZEBOV Ebola Virus Disease vaccine in African countries

World Health Organization WHO (2019) C_WHO

Revised working paper following AVAREF meeting February 2019. WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi... more

Download (85)

View PDF (432)

Provision and continuation of antiretroviral therapy during acute conflict: the experience of MSF in Central African Republic and Yemen

Ferreyra C., D. O’Brien, B. Alonso Conflict and Health (2018) C2

Unstable settings present challenges for the effective provision of antiretroviral treatment (ART). In this paper, we summarize the experience and results of providing ART and implementing contingency plans during acute instability in the Central African Republic (CAR) and Yemen.

Download (269)

View PDF (437)

Report of the Guideline Development Group Meeting on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis

World Health Organization (2017) C_WHO

A review of available evidence (2016). 28-29 June 2016; Geneva, Switzerland The END TB strategy.

Download (535)

View PDF (4394)

Monitoring and managing insecticide resistance in Aedes mosquito populations, Interim guidance for entomologists, 8 March 2016

World Health Organization WHO (2016) C_WHO

The use of safe and efficacious insecticides against the adult and larval populations of mosquito vectors is one of the most effective ways to rapidly interrupt transmission of Zika virus, as well as other viruses transmitted by Aedes mosquitoes such as chikungunya and dengue.

Download (385)

View PDF (585)

Policy Brief: Funding for HIV and AIDS Commodities in Kenya

Health Policy Project (2016) C2

Download (739)

View PDF (1112)

National Guidelines for Initiating and Managing Community -Based Family Planning Distribution (CBD) Services

Community Health Serivces Division and Family Health Division; Ministry of Health and Social Welfare Liberia USAID (2015)

Accessed February 2015

Download (416)

View PDF (997)

National HIV and AIDS Monitoring and Evaluation Plan 2015/2016 - 2019/2020

Uganda AIDS Commission; Ministry of Health, Uganda (2015) C1

Download (137)

View PDF (187)

Research Priorities for Zoonoses and Marginalized Infections

World Health Organization WHO (2012) C_WHO

WHO Technical Series 971

Download (195)

View PDF (320)

Synthesis of Focus Group Discussions with Health Workers in Rwanda

Tomas Lievens and Pieter Serneels Human Resources for Health (2006) C2

Health Systems for Outcomes Publication | This report summarizes the findings of a qualitative study on health workers’ performance and career in Rwanda to identify bottlenecks, strengths and shortcomings for human resources in the health sector, as perceived by both health workers and users of he... more

Download (333)

View PDF (605)

Uganda: Maama Kit - Making childbirth clean and safer

WHO, Ministry of Health Uganda (2006) C_WHO

Download (276)

View PDF (373)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (125)

View PDF (127)

Occupational stress, burnout and fatigue

World Health Organisation (WHO) (2022) C_WHO

Infogaphic

Download (117)

View PDF (165)

Preventing injuries and violence: an overview

World Health Organisation (WHO) (2022) C_WHO

This brief advocacy document highlights the burden, risks and prevention of injuries and violence, which took the lives of 4.4 million people in 2019 and constitute 8% of all deaths. Among the injury-related causes of death include road traffic crashes, drowning, falls, burns, poisoning and violence... more

Download (225)

View PDF (266)

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi... more

Clinical management and infection prevention and control for monkeypox recommended

Laboratory testing for Zika virus and dengue virus infections: interim guidance recommended

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV recommended

Monitoring and evaluation framework recommended

Therapeutics and COVID-19: living guideline, Updated 16 September 2022 recommended

Clinical management and infection prevention and control for monkeypox
recommended

Laboratory testing for Zika virus and dengue virus infections: interim guidance
recommended

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV
recommended

Monitoring and evaluation framework
recommended

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended